Atrial Fibrillation (AFib)
A randomized (Double Blind/Double Dummy) clinical trial to test if treatment with apixaban, compared with aspirin, will reduce the risk of stroke and systemic embolism in patients with device detected subclinical Atrial Fibrillation.
Principal Investigator: Hafiza Khan, MD
Locations: Arrhythmia Management
Sponsor: Hamilton Health Sciences through the Population Health Research Institute
IRB Number: 017-386
Trial Status: Enrolling
Exclusions: Adults only
Change in Care: Follow up every 6 months to refill study drug
Apixaban for the Reduction of Thrombo-Embolism in Patients With Device-Detected Sub-Clinical Atrial Fibrillation (ARTESiA)
Get Detailed Information On Clinicaltrials.gov »
Physicians are members of the medical staff at one of Baylor Scott & White Health's subsidiary, community or affiliated medical centers and are neither employees nor agents of those medical centers, Baylor Scott & White The Heart Hospital – Plano or Baylor Scott & White Health.